24381CSIGMA

Applied Filters:

Keyword:'24381CSIGMA'

facet content type:Technical Article

Showing 1-6 of 6 results for "24381CSIGMA" within Site Content

Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium

See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.

Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing

To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.

Can AAV Continue to Deliver the Promise of Gene Therapy?

The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.

Cell and Gene Therapy Manufacturing: Upstream Processing for AAV and Lentivirus Platforms

Minimize the complexities of cell and gene therapy production. Switch to upstream viral vector platforms to enhance scalability and simplify GMP manufacturing.

High Perf. Platforms for Lentiviral & AAV Mfg

Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.

Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.